慢性肺源性心脏病急性加重期患者血浆PCT、NT-ProBNP水平的变化及临床意义  

Level Changes and Clinical Significance of Procalcitonin and N‐terminal pro‐B‐type Natriuretic Peptide in Patients with Acute Exacerbation of Chronic Pulmonary Heart Disease

作　　者：蔡秋妍 陈璟[1] CAI Qiu‐yan;CHEN Jing(Huai'an TCM Hospital Affiliated to Nanjing University of Chinese Medicine,Huaian city,Jiangsu Province,223001,China)

机构地区：[1]南京中医药大学附属淮安中医院,江苏淮安223001

出　　处：《医学临床研究》2020年第5期724-726,共3页Journal of Clinical Research

基　　金：淮安市科技局重点研发计划(社会发展,HAS201612)。

摘　　要：[目的]探讨血浆降钙素原(PCT)和氨基末端B型脑钠肽前体(NT-proBNP)与慢性肺源性心脏病急性加重期(AECPHD)病情严重程度的相关性.[方法]选择35例慢性肺源性心脏病(CPHD)患者(CPHD组)和32例AECPHD患者(AECPHD组)作为研究对象,两组均按临床指南行规范性治疗.两组患者均进行痰细菌定量培养,分别检测治疗前后血浆PCT、NT-proBNP水平.[结果]治疗后,两组患者血浆PCT、NT-proBNP水平均低于治疗前,AECPHD组高于CPHD组,差异均有统计学意义(P<0.05).32例AECPHD患者中有9例PPM≥107 CFU/mL,阳性率为28.13%,35例CPHD患者中有3例PPM≥107 CFU/mL,阳性率为8.57%,AECPHD组PPM阳性率显著高于CPHD组,差异有统计学意义(χ^2=3.84,P<0.05).[结论]血浆PCT、NT-proBN检测水平可作为临床判断CPHD病情轻重及治疗效果的重要参考指标.[Objective]To explore clinical relationship of procalcitonin(PCT)and N‐terminal pro‐B‐type natri‐ureticpeptide(NT‐proBNP)with the severity of acute exacerbation of chronic pulmonary heart disease(AECPHD).[Methods]Patients with chronic pulmonary heart disease(n=35,the CPHD group)and with AECPHD(n=32),the AECPDH group)were selected for the study.All were treated routinely according to clinical guidelines.Sputum specimens were collected for bacterial quantitative culture before treatment.Levels of PCT and NT‐proBNP in patients with AECPHD and CPHD were measured before and after treatment.[Results]After treatment,the plasma PCT and NT‐proBNP levels of the two groups were lower than before treatment,while PCT and NT‐proBNP levels in patients with AECPHD were significantly higher than those in patients with CPHD.The difference was statistically significant(P<00.5).The positive rate of sputum culture(PPM≥107 CFU/mL)in patients with AECPHD was 281.3%(9/32),which was higher than that in patients with CPHD 85.7%(3/32,P<00.5).[Conclusion]PCT and NT‐proBNP levels can be used as potential indicators for the severity and treatment in patients with AECPHD.

关 键 词：肺心病/并发症 慢性病 利钠肽 脑 

分 类 号：R5416.1[医药卫生—心血管疾病]